ReviewTargeted oncology2018

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.

Bo Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.